“Bad to the Bone”
Thomas Viola RPh, C.C.P
Osteoporosis and its Treatment and the Link to Medication-Related Osteonecrosis
About 54 million Americans have osteoporosis and low bone mass, placing them at increased risk for osteoporosis. Studies suggest that approximately one in two women and up to one in four men age 50 and older will break a bone due to osteoporosis. Much misinformation exists about the current treatment guidelines for this insidious disease.
This program will provide participants with an overview of osteoporosis and the various agents available for its prevention and treatment. Using case scenarios, special emphasis will be given to dental patients taking bisphosphonates and other anti-resorptive medications and to developing patient management strategies essential for successful treatment planning and the management of these patients in everyday clinical situations.
Upon successful completion of this program, participants will be able to:
““Bad to the Bone”” is co-sponsored by Tribune Group GmbH. Tribune Group GmbH is a recognized ADA CERP and AGD PACE provider.
At the end of the webinar, after passing the C.E. Quiz, you will be able to download your ADA CERP and AGD PACE C.E. Certificates.
- Describe bone metabolism and the pathophysiology of osteoporosis.
- Identify the various agents used in the treatment of osteoporosis, including their mechanisms of action, adverse reactions, contraindications and dental considerations.
- Describe the role of anti-resorptive medications, including oral bisphosphonates, in the treatment of osteoporosis as well as their role in the pathophysiology of medication-associated osteonecrosis.
- Recognize current treatment guidelines for the successful management of dental patients receiving anti-resorptive medication therapy.